Moderna seeks COVID-19 vaccine authorization for kids younger than 6 years

Moderna said Wednesday that it will submit a request to the FDA “in the coming weeks” seeking authorization of its COVID-19 vaccine for children aged younger than 6 years.
The company announced findings from a phase 2/3 trial that indicated that a smaller dose of its messenger RNA vaccine induced an antibody response in young children that was similar to the one seen in adults who received a larger dose.
Vaccine efficacy during the trial — which took place during the omicron wave — was reduced but also consistent with adult data, Moderna said.
The study, called KidCOVE,

Moderna said Wednesday that it will submit a request to the FDA “in the coming weeks” seeking authorization of its COVID-19 vaccine for children aged younger than 6 years.
The company announced findings from a phase 2/3 trial that indicated that a smaller dose of its messenger RNA vaccine induced an antibody response in young children that was similar to the one seen in adults who received a larger dose.
Vaccine efficacy during the trial — which took place during the omicron wave — was reduced but also consistent with adult data, Moderna said.
The study, called KidCOVE,